Field Trip Health Company Profile

Field Trip Health | Company Profile

NASDAQ: FTRP

Latest Sector Updates

The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

Cybin Provides 2021 Year End Summary

atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

Field Trip Health aims to offer psychedelic-assisted psychotherapy across a network of clinics in North America, they currently operate from 6 clinical hubs and plan to roll out more clinics over the coming years. Through the ‘Discovery’ division they aim to develop the next generation of psychedelic molecules and conduct advanced research of plant-based psychedelics.

Field Trip listed on the CSE in October 2020, in March 2021 they closed a C$95m bought deal financing.

Stock information

Contact Information

Website: https://www.fieldtriphealth.com/

Investor Relations Website: https://www.meetfieldtrip.com/home/default.aspx

Contact Email:investors@fieldtriphealth.com

Corporate Presentation Link: click here

Latest Field Trip Health News

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET

June 17, 2021

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that ...

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

June 15, 2021

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, today announced that it ...